Affordable Access

Access to the full text

Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes

Authors
  • Edner, Natalie M.1
  • Heuts, Frank1
  • Thomas, Niclas1
  • Wang, Chun Jing1
  • Petersone, Lina1
  • Kenefeck, Rupert1
  • Kogimtzis, Alexandros1
  • Ovcinnikovs, Vitalijs1
  • Ross, Ellen M.1
  • Ntavli, Elisavet1
  • Elfaki, Yassin1
  • Eichmann, Martin2
  • Baptista, Roman2
  • Ambery, Philip3
  • Jermutus, Lutz4
  • Peakman, Mark2
  • Rosenthal, Miranda1
  • Walker, Lucy S. K.1
  • 1 University College London Division of Infection & Immunity, Royal Free Campus, London, UK , London (United Kingdom)
  • 2 King’s College London, London, UK , London (United Kingdom)
  • 3 BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden , Gothenburg (Sweden)
  • 4 BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK , Cambridge (United Kingdom)
Type
Published Article
Journal
Nature Immunology
Publisher
Springer Nature
Publication Date
Aug 03, 2020
Volume
21
Issue
10
Pages
1244–1255
Identifiers
DOI: 10.1038/s41590-020-0744-z
Source
Springer Nature
License
Yellow

Abstract

The CTLA-4–Ig fusion protein (abatacept) can have beneficial effects in autoimmune disease. Walker and colleagues show in mouse and human type 1 diabetes that abatacept targets pathogenic follicular helper T cells, and the frequencies of these cells at baseline can be used to stratify treatment responses in patients.

Report this publication

Statistics

Seen <100 times